Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
Chong Kun Dang Pharmaceutical
Study ID
NCT07532148
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
19 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • CKD-215 — DRUG
    2 tablets BID at 12-hour intervals for 7 days
  • D215 — DRUG
    2 tablets BID at 12-hour intervals for 7 days

Study Details

Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215

Key Dates

First listed
Apr 15, 2026
Start date
Jun 30, 2026
Status verified
Apr 2026
Primary completion
Jun 30, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental group 1
    Period 1: Test drug(CKD-215) Period 2: Reference drug(D215)
  • Experimental: Experimental group 2
    Period 1: Reference drug(D215) Period 2: Test drug(CKD-215)

Primary Outcome Measure

AUCtau [ Time Frame: 0~12 hours ]

Central Contacts

Find similar trials

Nationwide
Ovarian cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials

Related Studies